eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Availability

Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Availability

Document ID: FDA-2005-D-0208-0003
Document Type: Notice
Agency: Food And Drug Administration
Topics: No Topics associated with this document
Federal Register Number: E8-16395
View Document:  View as format pdf View as format html

Details Information

Document Subtype: NAD-Notice of Availability of Data
Received Date: July 16 2008, at 08:53 AM Eastern Daylight Time
Start-End Page: 41087 - 41088
Page Count: 2
Comment Start Date: July 17 2008, at 12:00 AM Eastern Standard Time

Comments

Total: 0
No comments posted.

Related Documents

Total: 0
No documents available.